There are several interesting new publications worth commenting on this morning — all in the evolving research field as opposed to current clinical practice:
- Angiogenic effect of a specific statin on prostate cancer development
- Synergistic impact of calcitriol on cryotherapy
- Hybrid imaging techniques and prostate cancer
- GTI-2040 in treatment of CRPC
Wang et al. have studied the effects of a variety of pharmaceuticals with angiogenic effects in a laboratory model from prostate cancer development. Their data suggest that a specific statin (rosuvastatin/Crestor) may be able to suppress the development of prostate cancer under certain circumstances.
Also based on work using a laboratory model, Kimura et al. have shown that giving calcitriol (vitamin D3) in combination with cryotherapy may have a synergistic effect leading to better outcomes after cryotherapy.
Beer et al. have reviewed available data on the evolution of hybrid imaging techniques in prostate cancer. The article specifically addresses the combination of single positron emission computer tomography (SPECT) with standard computer tomography (CT) scanning and positron emission tomography (PET) scanning in order to identify small amounts of prostate cancer in men with recurrent disease after first-line therapy. They also discuss the future potential of hybrid magnetic resonance-PET (MR-PET) imaging.
Sridhar et al. have reported that the investigational agent GTI-2040 (an antisense oligonucleotide), when combined with docetaxel and predisone for the first-line treatment of men with castration-resistant prostate cancer (CRPC), is not sufficiently active to consider further development using the dose and schedule tested in a recent Phase II clinical trial.